Business Insider

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with ...

RADNOR, Pa., Dec. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug ...
Yahoo Finance

NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted ...

ZYESAMI is available to patients who have progressed despite treatment with remdesivir and other approved medicines and who are not able to participate in the NIH trial NRx manufacturing program now ...
Business Insider

NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19

RADNOR, Pa., July 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10: ...
Nasdaq

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA ...
Yahoo Finance

Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)

GENEVA, SWITZERLAND / ACCESSWIRE / October 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from ...
Nasdaq

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

- Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung - ...
BGR

This Might Be The Breakthrough Coronavirus Cure We've Been Waiting For

A potential coronavirus cure that can reduce recovery time and prevent COVID-19 complications is now in Phase 2/3 testing. The drug is called RLF-100 or aviptadil, and it also received emergency use ...
The Mercury

NeuroRx Announces ZyesamiTM (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

RADNOR, Pa., April 6, 2021 /PRNewswire/ — NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs ...
clinicaladvisor.com

Aviptadil Not Linked to Improvement in COVID-19 Hypoxemic Respiratory Failure

Credit: Getty Images. The TESICO trial compared IV aviptadil vs placebo and IV remdesivir vs placebo in patients with acute hypoxemic respiratory failure due to COVID-19. Aviptadil did not improve ...
Daily Mail

Erectile dysfunction drug aviptadil may also treat Covid-19, experts believe

A drug used for erectile dysfunction has the potential to treat critically ill Covid-19 patients, scientists say. Aviptadil — branded as Invicorp in the UK but not yet marketed in America — has been ...
Monthly Prescribing Reference

Aviptadil Gets Orphan Drug Status for Sarcoidosis

RLF-100 (aviptadil) is an inhaled, synthetic formulation of vasoactive intestinal peptide (VIP) for the treatment of sarcoidosis. The Food and Drug Administration (FDA) has granted Orphan Drug ...
Business Wire

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

RADNOR, Pa. & GENEVA--(BUSINESS WIRE)--NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory ...